Price Chart

Key Stats

Customize
Expense Ratio Discount or Premium to NAV Total Assets Under Management 30-Day Average Daily Volume
1.07% 0.21% 69.71M 3.767M
Dividend Yield Turnover Ratio 1 Year Fund Level Flows Max Drawdown (All)
0.00% 0.00% 210.78M Upgrade

Basic Info

Investment Strategy
The investment seeks daily investment results, before fees and expenses, of 300% of the inverse of the daily performance of the S&P Biotechnology Select Industry Index. The fund, under normal circumstances, invests in swap agreements, futures contracts, short positions or other financial instruments that, in combination, provide inverse (opposite) or short leveraged exposure to the index equal to at least 80% of the fund's net assets (plus borrowing for investment purposes). The index is designed to measure the performance of the biotechnology sub-industry based on the Global Industry Classification Standards ("GICS"). The fund is non-diversified.
General
Security Type Exchange-Traded Fund
Equity Style --
Fixed Income Style --
Broad Asset Class Alternative
Broad Category Alternative
Category Name Trading--Inverse Equity
Category Index S&P 500 TR USD
Prospectus Objective Specialty - Technology
Fund Owner Firm Name Direxion Funds
Prospectus Benchmark Index
S&P Biotechnology Select Industry TR USD -300.0%
Broad Asset Class Benchmark Index
^MSACWINTR 100.0%
Manager Tenure
Paul Brigandi 5.85 yrs
Tony Ng 5.51 yrs

Net Fund Flows Versus Category

View Net Fund Flows. Upgrade now.
1M
3M
6M
YTD
1Y
3Y
5Y
10Y
 
80.00B
60.00B
40.00B
20.00B
0
-20.00B
1 Month
% Rank: --
-- Category Low
-- Category High
1 Year
% Rank: 17
210.78M
-249.84M Category Low
2.454B Category High
3 Months
% Rank: --
-- Category Low
-- Category High
3 Years
% Rank: --
-- Category Low
-- Category High
6 Months
% Rank: --
-- Category Low
-- Category High
5 Years
% Rank: --
-- Category Low
-- Category High
YTD
% Rank: --
-- Category Low
-- Category High
10 Years
% Rank: --
-- Category Low
-- Category High
As of March 31, 2021

Performance Versus Category

 
20%
15%
10%
5%
0
View Category Returns. Upgrade now.
Name
1M
3M
YTD
1Y
3Y
5Y
10Y
15Y
Total Return (Price)
--
--
--
--
--
--
--
--
Total Return (NAV)
--
--
--
--
--
--
--
--
Category Rtn. (NAV)
--
--
--
--
--
--
--
--
% Rank in Cat (NAV)
--
--
--
--
--
--
--
--
As of April 13, 2021. Returns for periods of 1 year and above are annualized.

Annual Total Returns Versus Peers

Edit comparables
Name
2014
2015
2016
2017
2018
2019
2020
YTD
--
--
-39.05%
-75.67%
-6.26%
-70.81%
-89.74%
-1.27%
4.16%
-2.36%
7.86%
23.97%
-9.41%
26.60%
16.25%
8.14%
--
--
-62.90%
149.1%
-57.60%
75.51%
74.66%
-33.29%
-64.31%
-25.00%
-73.16%
-69.39%
-19.39%
-83.81%
-92.89%
-52.34%
-46.11%
-31.13%
-43.39%
-60.81%
-19.14%
-73.77%
-87.78%
-31.42%
-55.43%
-37.59%
21.87%
-36.98%
5.18%
-41.01%
-56.01%
-3.23%
As of April 13, 2021.

Fundamentals

General
Distribution Yield Upgrade
Dividend Yield TTM (4-13-21) 0.00%
30-Day SEC Yield --
7-Day SEC Yield --
Number of Holdings Upgrade
Stock
Weighted Average PE Ratio --
Weighted Average Price to Sales Ratio --
Weighted Average Price to Book Ratio --
Weighted Median ROE --
Weighted Median ROA --
Forecasted Dividend Yield --
Forecasted PE Ratio --
Forecasted Price to Sales Ratio --
Forecasted Price to Book Ratio --
As of April 12, 2021

Growth Estimates

Forecasted 5 Yr Earnings Growth --
Forecasted Book Value Growth --
Forecasted Cash Flow Growth --
Forecasted Earnings Growth --
Forecasted Revenue Growth --
As of April 12, 2021

Asset Allocation

As of April 12, 2021.
Type % Net % Long % Short
Cash 123.3% Upgrade Upgrade
Stock -23.29% Upgrade Upgrade
Bond 0.00% Upgrade Upgrade
Convertible 0.00% Upgrade Upgrade
Preferred 0.00% Upgrade Upgrade
Other 0.00% Upgrade Upgrade

Top 3 Holdings

Name % Weight Price % Change
Goldman Sachs FS Treasury Intms Instl 58.97% 1.00 0.00%
Dreyfus Government Secs Cash Mgmt Admin 20.34% 1.00 0.00%
S&P Biotechnology Select Industry Index Swap
-23.29% -- --

Basic Info

Investment Strategy
The investment seeks daily investment results, before fees and expenses, of 300% of the inverse of the daily performance of the S&P Biotechnology Select Industry Index. The fund, under normal circumstances, invests in swap agreements, futures contracts, short positions or other financial instruments that, in combination, provide inverse (opposite) or short leveraged exposure to the index equal to at least 80% of the fund's net assets (plus borrowing for investment purposes). The index is designed to measure the performance of the biotechnology sub-industry based on the Global Industry Classification Standards ("GICS"). The fund is non-diversified.
General
Security Type Exchange-Traded Fund
Equity Style --
Fixed Income Style --
Broad Asset Class Alternative
Broad Category Alternative
Category Name Trading--Inverse Equity
Category Index S&P 500 TR USD
Prospectus Objective Specialty - Technology
Fund Owner Firm Name Direxion Funds
Prospectus Benchmark Index
S&P Biotechnology Select Industry TR USD -300.0%
Broad Asset Class Benchmark Index
^MSACWINTR 100.0%
Manager Tenure
Paul Brigandi 5.85 yrs
Tony Ng 5.51 yrs

Fundamentals

General
Distribution Yield Upgrade
Dividend Yield TTM (4-13-21) 0.00%
30-Day SEC Yield --
7-Day SEC Yield --
Number of Holdings Upgrade
Stock
Weighted Average PE Ratio --
Weighted Average Price to Sales Ratio --
Weighted Average Price to Book Ratio --
Weighted Median ROE --
Weighted Median ROA --
Forecasted Dividend Yield --
Forecasted PE Ratio --
Forecasted Price to Sales Ratio --
Forecasted Price to Book Ratio --
As of April 12, 2021

Growth Estimates

Forecasted 5 Yr Earnings Growth --
Forecasted Book Value Growth --
Forecasted Cash Flow Growth --
Forecasted Earnings Growth --
Forecasted Revenue Growth --
As of April 12, 2021

Fund Details

Key Dates
Inception Date 5/28/2015
Last Annual Report Date 10/31/2020
Last Prospectus Date 2/28/2021
Attributes
Enhanced Index Fund No
Index Fund Yes
Inverse Fund Yes
Leveraged Fund Yes
Fund of Funds No
Currency Hedged Fund No
Synthetic Replication Fund No
Has Dividend Investment Plan No
Socially Responsible Fund No